From my ChatGPT updating me a few minutes ago,
CYTODYN/CLOVER UPDATE — SEPTEMBER 12, 2026
A meaningful competitive development in metastatic colorectal cancer is worth watching.
The FDA has extended its review of Exelixis’ zanzalintinib + atezolizumab application by three months, moving the decision date to March 3, 2027. The application is based largely on the Phase 3 STELLAR-303 trial involving 901 patients with previously treated metastatic colorectal cancer.
The numbers are particularly interesting when thinking about CLOVER:
• Overall Survival: 10.9 months vs. 9.4 months with regorafenib
• Progression-Free Survival: 3.7 months vs. 2.0 months
• Overall Response Rate (ORR): only 4% vs. 1%
Despite an ORR of only 4%, the trial demonstrated a statistically significant survival benefit.
WHY THIS MATTERS FOR LERONLIMAB AND CLOVER
This gives us another useful benchmark for evaluating CLOVER.
If leronlimab + TAS-102 (Lonsurf) + bevacizumab can produce a clearly higher response rate in a similarly difficult late-line metastatic colorectal cancer population, it could become very interesting.
For example, if CLOVER ultimately produces a double-digit ORR — particularly 15–20% or higher — accompanied by meaningful duration of response, favorable safety and strong ctDNA reductions, the results would stand out considerably against some existing late-line CRC therapies.
The Exelixis results also remind us of something important:
ORR alone will not determine leronlimab's future.
The FDA will ultimately care about the complete picture:
• Overall Response Rate (ORR)
• Duration of Response (DOR)
• Progression-Free Survival (PFS)
• Overall Survival (OS)
• Safety and tolerability
• ctDNA/molecular response
• Evidence that the 700-mg dose performs better than 350 mg
The Natera/Signatera ctDNA data could therefore become particularly valuable if deep molecular responses correspond with actual tumor shrinkage and durable clinical responses.
WHERE THINGS STAND
As of September 12, I have not seen a new CytoDyn announcement containing CLOVER ORR, DOR, PFS or final Natera ctDNA results.
So the major event we are waiting for remains the actual CLOVER efficacy data.
MY TAKEAWAY
The bar in late-line metastatic colorectal cancer is not extraordinarily high, but the FDA clearly wants evidence that translates into meaningful patient benefit.
If CLOVER eventually demonstrates:
1. A strong double-digit ORR,
2. Durable responses,
3. Favorable safety,
4. Major ctDNA reductions that correlate with clinical response, and
5. A convincing advantage at the 700-mg dose,
I believe the leronlimab story changes substantially.
At that point, the question may no longer be simply whether leronlimab works.
The bigger questions could become:
What regulatory pathway will the FDA allow?
And which pharmaceutical company will want to partner with CytoDyn?
For now, the data still have to prove the case.
CYTODYN/CLOVER UPDATE — SEPTEMBER 12, 2026
A meaningful competitive development in metastatic colorectal cancer is worth watching.
The FDA has extended its review of Exelixis’ zanzalintinib + atezolizumab application by three months, moving the decision date to March 3, 2027. The application is based largely on the Phase 3 STELLAR-303 trial involving 901 patients with previously treated metastatic colorectal cancer.
The numbers are particularly interesting when thinking about CLOVER:
• Overall Survival: 10.9 months vs. 9.4 months with regorafenib
• Progression-Free Survival: 3.7 months vs. 2.0 months
• Overall Response Rate (ORR): only 4% vs. 1%
Despite an ORR of only 4%, the trial demonstrated a statistically significant survival benefit.
WHY THIS MATTERS FOR LERONLIMAB AND CLOVER
This gives us another useful benchmark for evaluating CLOVER.
If leronlimab + TAS-102 (Lonsurf) + bevacizumab can produce a clearly higher response rate in a similarly difficult late-line metastatic colorectal cancer population, it could become very interesting.
For example, if CLOVER ultimately produces a double-digit ORR — particularly 15–20% or higher — accompanied by meaningful duration of response, favorable safety and strong ctDNA reductions, the results would stand out considerably against some existing late-line CRC therapies.
The Exelixis results also remind us of something important:
ORR alone will not determine leronlimab's future.
The FDA will ultimately care about the complete picture:
• Overall Response Rate (ORR)
• Duration of Response (DOR)
• Progression-Free Survival (PFS)
• Overall Survival (OS)
• Safety and tolerability
• ctDNA/molecular response
• Evidence that the 700-mg dose performs better than 350 mg
The Natera/Signatera ctDNA data could therefore become particularly valuable if deep molecular responses correspond with actual tumor shrinkage and durable clinical responses.
WHERE THINGS STAND
As of September 12, I have not seen a new CytoDyn announcement containing CLOVER ORR, DOR, PFS or final Natera ctDNA results.
So the major event we are waiting for remains the actual CLOVER efficacy data.
MY TAKEAWAY
The bar in late-line metastatic colorectal cancer is not extraordinarily high, but the FDA clearly wants evidence that translates into meaningful patient benefit.
If CLOVER eventually demonstrates:
1. A strong double-digit ORR,
2. Durable responses,
3. Favorable safety,
4. Major ctDNA reductions that correlate with clinical response, and
5. A convincing advantage at the 700-mg dose,
I believe the leronlimab story changes substantially.
At that point, the question may no longer be simply whether leronlimab works.
The bigger questions could become:
What regulatory pathway will the FDA allow?
And which pharmaceutical company will want to partner with CytoDyn?
For now, the data still have to prove the case.
2
